TNXP - Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 | Benzinga
CHATHAM, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced two oral presentations and a poster presentation at the American Transplant Congress 2024, being held June 1-5, 2024 at the Pennsylvania Convention Center, Philadelphia, Pa. Details on each presentation can be found below.
Copies of the Company's poster presentations will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the American Transplant Congress website here.
| Oral Presentations Details |
| Presenter: |
| Kohei Kinoshita, M.D., Center for Transplantation Sciences, Massachusetts General Hospital |
| Title: |
| Combined Blockade of the CD154 and CD28 Co-Stimulation Pathways Attenuates Pathogenic Alloimmunity and Prolongs Survival in Cynomolgus Cardiac Allografts |
| Location: |
| 109-AB‚ Level 1 |
| Abstract: |
| 860 |
| Date/Time: |
| Tuesday, June 4, 2024, 9:45 a.m. ET |
| Presenter: |
| Ikechukwu Ileka, M.D., Massachusetts General Hospital and Harvard Medical School |
| Title: |
| Extended Survival of 9- and 10-Gene-Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade-Based Immunosuppression |
| Location: |
| 114 - Nutter Theater‚ Level 1 |
| Abstract: |
| 932 |